Sebastian Kreuz, PhD

Sebastian is an accomplished investment manager at the Boehringer Ingelheim Venture Fund (BIVF), where he specializes in innovative life science investments across Europe. With over 15 years of experience in translational research and drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities.

Sebastian embarked on his industrial career in 2004, joining Boehringer Ingelheim (BI) as a research scientist. His initial focus was on functional genomics approaches for early drug concept research. Over the years, he has held numerous positions of increasing responsibility within BI’s R&D organization, thereby further expanding his expertise in drug discovery and gaining significant leadership experience in both early and late-stage projects.

Since joining the BIVF in 2019, Sebastian has served on the boards of several BIVF portfolio companies, including Abalos Therapeutics, Quantro Therapeutics, Rewind Therapeutics, Smartbax, and Topas Therapeutics. Until recently, he also served as a Board observer at Centauri Therapeutics.

Sebastian studied Technical Biology in Stuttgart, Germany, and holds a PhD in Molecular Cell Biology and Immunology.